Follow Us GraphicFacebook IconTwitter IconLinkedIn Icon
Search Graphic

Reports on Amag

Sort by

Antares (ATRS, Buy, $3.51); AMAG Pharmaceuticals (AMAG, $11.73) First Thoughts about How the PROLONG Study Could Affect Makena Usage

Monday, March 11, 2019 · 11:04 am

Read More

AMAG Pharmaceuticals: Trying to Project 2019 Sales for the Makena Franchise (AMAG, $24.45, Buy)

Friday, August 17, 2018 · 9:32 am

Read More

AMAG Pharmaceuticals: Strong Launch of Subcu Makena and Pending Sale of Cord Blood Registry is Encouraging (AMAG, $23.55, Buy)

Friday, June 15, 2018 · 11:44 am

Read More

AMAG:  It Is Early Days, but the Launch of the Subcutaneous Dosage Form of Makena Seems to be Going Very Well (AMAG, Buy, $21.17)

Monday, May 7, 2018 · 11:44 am

Read More

AMAG: Upgrading to Buy Based on an In-Depth Analysis of the Outlook for Makena Over the 2018 to 2020 Period (AMAG, Buy, $21.10))

Friday, April 13, 2018 · 5:20 pm

Read More

AMAG Pharmaceuticals: Will FDA Approve Makena SC (AMAG, Neutral, $21.75)

Friday, February 3, 2017 · 10:15 am

Read More

AMAG and Antares: Update on the Development of Makena SC (AMAG, Neutral, $24.40) (ATRS, Buy, $2.04)

Thursday, January 26, 2017 · 9:44 am

Read More

AMAG Pharmaceuticals: Initiation of Research on a Complex but Potentially Very Interesting Investment Situation (AMAG, Neutral, $24)

Sunday, June 26, 2016 · 9:11 am

Read More

There are 8 reports on file.

« Back to Company Reports Index